Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654914 | 1.00 | KDM4E (0.55) | KDM4ELMNAPTGER1PTGER4PTGER3 | |
| SCHEMBL4969599 | 0.93 | AKR1C3 (0.52) | KDM4ELMNAAKR1C3ALDH1A1LTB4R | |
| SCHEMBL4969588 | 0.93 | AKR1C3 (0.52) | KDM4ELMNAAKR1C3ALDH1A1LTB4R | |
| SCHEMBL5502668 | 0.89 | AKR1C3 (0.46) | KDM4ELMNAAKR1C3LTB4RLTB4R2 | |
| SCHEMBL5502667 | 0.89 | AKR1C3 (0.46) | KDM4ELMNAAKR1C3LTB4RLTB4R2 | |
| SCHEMBL4972553 | 0.85 | FFAR1 (0.48) | PTGER1PTGER4PTGER3PTGER2APP | |
| SCHEMBL5653570 | 0.84 | AKR1C3 (0.43) | AKR1C3APPLTB4RLTB4R2 | |
| SCHEMBL5653574 | 0.84 | AKR1C3 (0.43) | AKR1C3APPLTB4RLTB4R2 | |
| SCHEMBL4969332 | 0.84 | PTGER4 (0.48) | KDM4ELMNAPTGER1PTGER4PTGER3 | |
| SCHEMBL4969336 | 0.84 | PTGER4 (0.48) | KDM4ELMNAPTGER1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | claimed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | KDM4E 3918/4885LMNA 2446/4885PTGER1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.